Serial measurement of high-sensitivity troponin i and cardiovascular outcomes in patients with type 2 diabetes mellitus in the examine trial (examination of cardiovascular outcomes with alogliptin versus standard of care)

Circulation

Volumn 135, Issue 20, 2017, Pages 1911-1921

  Cavender, Matthew A ^a   White, William B ^b   Jarolim, Petr ^c   Bakris, George L ^e   Cushman, William C ^f   Kupfer, Stuart ^g   Gao, Qi ^h   Mehta, Cyrus R ⁱ   Zannad, Faiez ^j   Cannon, Christopher P ^h   Morrow, David A ^d  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^c TIMI Study Group   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e UNIVERSITY OF CHICAGO   (United States)

^f UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^g TAKEDA DEVELOPMENT CENTER AMERICAS   (United States)

^h HARVARD CLINICAL RESEARCH INSTITUTE   (United States)

ⁱ HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^j UNIVERSITÉ DE LORRAINE   (France)

more..

Author keywords

Acute coronary syndrome; Cardiac biomarkers; Secondary prevention; Troponin; Type 2 diabetes mellitus

Indexed keywords

ALOGLIPTIN; GLYCOSYLATED HEMOGLOBIN; INSULIN; TROPONIN; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; PIPERIDINE DERIVATIVE; TROPONIN I; URACIL;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HEART FAILURE; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; ANALOGS AND DERIVATIVES; BLOOD; COMPARATIVE STUDY; DIABETES MELLITUS, TYPE 2; HEALTH CARE QUALITY; MIDDLE AGED; TREATMENT OUTCOME; TRENDS;

ACUTE CORONARY SYNDROME; AGED; BIOMARKERS; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PIPERIDINES; STANDARD OF CARE; TREATMENT OUTCOME; TROPONIN I; URACIL;

EID: 85017227814     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.116.024632     Document Type: Article

References (33)

1. Gregg EW, Li Y, Wang J, Burrows NR, Ali MK, Rolka D, Williams DE, Geiss L. Changes in diabetes-related complications in the United States, 1990-2010. N Engl J Med. 2014;370:1514-1523. doi: 10.1056/NEJMoa1310799.
2. Cavender MA, Scirica BM, Bonaca MP, Angiolillo DJ, Dalby AJ, Dell-borg M, Morais J, Murphy SA, Ophuis TO, Tendera M, Braunwald E, Morrow DA. Vorapaxar in patients with diabetes mellitus and previous myocardial infarction: findings from the thrombin receptor antagonist in secondary prevention of atherothrombotic isch-emic events: TIMI 50 trial. Circulation. 2015;131:1047-1053. doi: 10.1161/CIRCULATIONAHA.114.013774.
3. Cavender MA, Steg PG, Smith SC Jr, Eagle K, Ohman EM, Goto S, Kuder J, Im K, Wilson PW, Bhatt DL; REACH Registry Investigators. Impact of diabetes mellitus on hospitalization for heart failure, cardiovascular events, and death: outcomes at 4 years from the Reduction of Atherothrombosis for Continued Health (REACH) registry. Circulation. 2015;132:923-931. doi: 10.1161/CIRCULATIONAHA. 114.014796.
4. Sabatine MS, Morrow DA, de Lemos JA, Gibson CM, Murphy SA, Rifai N, McCabe C, Antman EM, Cannon CP, Braunwald E. Multi-marker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation. 2002;105:1760-1763.
5. Cavender MA, Ohman EM. What do you need to know before performing a percutaneous coronary intervention? Circulation. 2008;118:609-611. doi: 10.1161/CIRCULATIONAHA. 108.791848.
6. de Lemos JA, Drazner MH, Omland T, Ayers CR, Khera A, Rohatgi A, Hashim I, Berry JD, Das SR, Morrow DA, McGuire DK. Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. JAMA. 2010;304:2503-2512. doi: 10.1001/jama.2010.1768.
7. Morrow DA, Cannon CP, Jesse RL, Newby LK, Ravkilde J, Stor-row AB, Wu AH, Christenson RH, Apple FS, Francis G, Tang W; National Academy of Clinical Biochemistry. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: clinical characteristics and utilization of biochemical markers in acute coronary syndromes. Clin Chem. 2007;53:552-574. doi: 10.1373/clinchem.2006.084194.
8. Everett BM, Brooks MM, Vlachos HE, Chaitman BR, Frye RL, Bhatt DL; BARI 2D Study Group. Troponin and cardiac events in stable ischemic heart disease and diabetes. N Engl J Med. 2015;373:610-620. doi: 10.1056/NEJMoa1415921.
9. White WB, Bakris GL, Bergenstal RM, Cannon CP, Cushman WC, Fleck P, Heller S, Mehta C, Nissen SE, Perez A, Wilson C, Zan-nad F. EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes melli-tus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome. Am Heart J. 2011;162:620.e1-626.e1. doi: 10.1016/j.ahj. 2011.08.004.
10. White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Cushman WC, Zannad F; EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369:1327-1335. doi: 10.1056/NEJMoa1305889.
11. Hicks KA, Tcheng JE, Bozkurt B, Chaitman BR, Cutlip DE, Farb A, Fonarow GC, Jacobs JP, Jaff MR, Lichtman JH, Limacher MC, Mahaffey KW, Mehran R, Nissen SE, Smith EE, Targum SL. 2014 ACC/AHA key data elements and definitions for cardiovascular endpoint events in clinical trials: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards). J Am Coll Cardiol. 2015;66:403-469. doi: 10.1016/j.jacc.2014.12.018.
12. Zannad F, Cannon CP, Cushman WC, Bakris GL, Menon V, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Lam H, White WB; EXAMINE Investigators. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet. 2015;385:2067-2076. doi: 10.1016/S0140-6736(14)62225-X.
13. Lipowsky C, Laird D, Workman R, Ramp J, Drengler S and Gardiner M. Development of a highly sensitive immunoassay for cardiac troponin I for the ARCHITECT i2000SR and i1000SR analyzers. Clin Chem. 2012;58:A5.
14. Jarolim P. High sensitivity cardiac troponin assays in the clinical laboratories. Clin Chem Lab Med. 2015;53:635-652. doi: 10.1515/cclm-2014-0565.
15. Apple FS, Jaffe AS, Collinson P, Mockel M, Ordonez-Llanos J, Lin-dahl B, Hollander J, Plebani M, Than M, Chan MH; International Federation of Clinical Chemistry (IFCC) Task Force on Clinical Applications of Cardiac Bio-Markers. IFCC educational materials on selected analytical and clinical applications of high sensitivity cardiac troponin assays. Clin Biochem. 2015;48:201-203. doi: 10.1016/j.clinbiochem.2014.08.021.
16. Everett BM, Zeller T, Glynn RJ, Ridker PM, Blankenberg S. High-sensitivity cardiac troponin I and B-type natriuretic peptide as predictors of vascular events in primary prevention: impact of statin therapy. Circulation. 2015;131:1851-1860. doi: 10.1161/CIRCULATIONAHA.114.014522.
17. Omland T, Pfeffer MA, Solomon SD, de Lemos JA, Røsjø H, Saltyte Benth J, Maggioni A, Domanski MJ, Rouleau JL, Saba-tine MS, Braunwald E; PEACE Investigators. Prognostic value of cardiac troponin I measured with a highly sensitive assay in patients with stable coronary artery disease. J Am Coll Cardiol. 2013;61:1240-1249. doi: 10.1016/j.jacc.2012.12.026.
18. Omland T, de Lemos JA, Holmen OL, Dalen H, Benth J, Nygård S, Hveem K, Røsjø H. Impact of sex on the prognostic value of high-sensitivity cardiac troponin I in the general population: the HUNT study. Clin Chem. 2015;61:646-656. doi: 10.1373/clinchem.2014.234369.
19. Cullen L, Greenslade JH, Carlton EW, Than M, Pickering JW, Ho A, Greaves K, Berndt SL, Body R, Ryan K, Parsonage WA. Sex-specific versus overall cut points for a high sensitivity troponin I assay in predicting 1-year outcomes in emergency patients presenting with chest pain. Heart. 2016;102:120-126. doi: 10.1136/heartjnl-2015-308506.
20. Bohula May EA, Bonaca MP, Jarolim P, Antman EM, Braunwald E, Giugliano RP, Newby LK, Sabatine MS, Morrow DA. Prognostic performance of a high-sensitivity cardiac troponin I assay in patients with non-ST-elevation acute coronary syndrome. Clin Chem. 2014;60:158-164. doi: 10.1373/clinchem.2013.206441.
21. Antman EM, Tanasijevic MJ, Thompson B, Schactman M, Mc-Cabe CH, Cannon CP, Fischer GA, Fung AY, Thompson C, Wybenga D, Braunwald E. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med. 1996;335:1342-1349. doi: 10.1056/NEJM199610313351802.
22. Morrow DA, Cannon CP, Rifai N, Frey MJ, Vicari R, Lakkis N, Robertson DH, Hille DA, DeLucca PT, DiBattiste PM, Demopoulos LA, Weintraub WS, Braunwald E; TACTICS-TIMI 18 Investigators. Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: results from a randomized trial. JAMA. 2001;286:2405-2412.
23. Kavsak PA, Don-Wauchope AC, Hill SA, Worster A. Acceptable analytical variation may exceed high-sensitivity cardiac troponin I cutoffs in early rule-out and rule-in acute myocardial infarction algorithms. Clin Chem. 2016;62:887-889. doi: 10.1373/clinchem.2016.255448.
24. Simpson AJ, Potter JM, Koerbin G, Oakman C, Cullen L, Wilkes GJ, Scanlan SL, Parsonage W, Hickman PE. Use of observed within-person variation of cardiac troponin in emergency department patients for determination of biological variation and percentage and absolute reference change values. Clin Chem. 2014;60:848-854. doi: 10.1373/clinchem.2013.219410.
25. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837-1847.
26. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson PWF. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(suppl 2):S1-S45. doi: 10.1161/01.cir.0000437738.63853.7a.
27. Bonaca MP, O'Malley RG, Jarolim P, Scirica BM, Murphy SA, Conrad MJ, Cannon CP, White HD, Braunwald E, Morrow DA, Saba-tine MS. Serial cardiac troponin measured using a high-sensitivity assay in stable patients with ischemic heart disease. J Am Coll Cardiol. 2016;68:322-323. doi: 10.1016/j.jacc.2016.04.046.
28. White HD, Tonkin A, Simes J, Stewart R, Mann K, Thompson P, Colquhoun D, West M, Nestel P, Sullivan D, Keech AC, Hunt D, Blankenberg S; LIPID Study Investigators. Association of contemporary sensitive troponin I levels at baseline and change at 1 year with long-term coronary events following myocardial infarction or unstable angina: results from the LIPID Study (Long-Term Intervention With Pravastatin in Ischaemic Disease). J Am Coll Cardiol. 2014;63:345-354. doi: 10.1016/j.jacc.2013.08.1643.
29. Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG, Normand SL, Braunwald E, Wiviott SD, Cohen DJ, Holmes DR Jr, Krucoff MW, Hermiller J, Dauerman HL, Simon DI, Kandzari DE, Garratt KN, Lee DP, Pow TK, Ver Lee P, Rinaldi MJ, Massaro JM; DAPT Study Investigators. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014;371:2155-2166. doi: 10.1056/NEJMoa1409312.
30. Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, Magnani G, Bansilal S, Fish MP, Im K, Bengtsson O, Oude Ophuis T, Budaj A, Theroux P, Ruda M, Hamm C, Goto S, Spinar J, Nicolau JC, Kiss RG, Murphy SA, Wiviott SD, Held P, Braunwald E, Sa-batine MS; PEGASUS-TIMI 54 Steering Committee and Investigators. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015;372:1791-1800. doi: 10.1056/NEJMoa1500857.
31. Bhatt DL, Bonaca MP, Bansilal S, Angiolillo DJ, Cohen M, Storey RF, Im K, Murphy SA, Held P, Braunwald E, Sabatine MS and Steg PG. Reduction in ischemic events with ticagrelor in diabetic patients: from the PEGASUS-TIMI 54 trial. J Am Coll Cardiol. 2016;67:2732-2740.
32. Nissen SE, Wolski K, Topol EJ. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA. 2005;294:2581-2586. doi: 10.1001/jama.294.20.joc50147.
33. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD. Third universal definition of myocardial infarction. Euro Heart J. 2012;33:2551-2567.